Musculoskeletal functional outcomes in children with osteogenesis imperfecta: Associations with disease severity and pamidronate therapy

Journal of Pediatric Orthopaedics

Volumn 34, Issue 1, 2014, Pages 118-122

  Sousa, Ted ^a   Bompadre, Viviana ^b   White, Klane K ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

Bisphosphonates; Osteogenesis imperfecta; Pamidronate; Pediatric Outcomes Data Collection Instrument (PODCI)

Indexed keywords

PAMIDRONIC ACID;

ARTICLE; BONE DENSITY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HAPPINESS; HUMAN; LONG BONE; LUMBAR SPINE; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OSTEOGENESIS IMPERFECTA; OUTCOME ASSESSMENT; PAIN; PEDIATRIC OUTCOMES DATA COLLECTION INSTRUMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SCORING SYSTEM; SPORT;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MOTOR ACTIVITY; MUSCULOSKELETAL SYSTEM; OSTEOGENESIS IMPERFECTA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84890558313     PISSN: 02716798     EISSN: 15392570     Source Type: Journal    
DOI: 10.1097/BPO.0b013e3182a006a0     Document Type: Article

References (26)

1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-116.
2. Van Dijk FS, Pals G, Van Rijn RR, et al. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53:1-5.
3. Barnes AM, Carter EM, Cabral WA, et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med. 2010;362:521-528.
4. Van Dijk FS, Cobben JM, Kariminejad A, et al. Osteogenesis imperfecta: a review with clinical examples. Mol Syndromol. 2011;2:1-20.
5. Warman ML, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A. 2011;155A:943-968.
6. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;4: CD005088.
7. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363: 1377-1385.
8. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952.
9. Glorieux FH. Bisphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2000;13(suppl 2): 989-992.
10. Lee YS, Low SL, Lim LA, et al. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr. 2001;160:641-644.
11. DiMeglio LA, Ford L, McClintock C, et al. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone. 2004;35:1038-1045.
12. Forin V, Arabi A, Guigonis V, et al. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. Joint Bone Spine. 2005;72:313-318.
13. Salehpour S, Tavakkoli S. Cyclic pamidronate therapy in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2010;23:73-80.
14. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006;21:132-140.
15. Åström E, Söderhäll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86:356-364.
16. Daltroy LH, Liang MH, Fossel AH, et al. The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. Pediatric Outcomes Instrument Development Group. Pediatric Orthopaedic Society of North America. J Pediatr Orthop. 1998;18:561-571.
17. Damiano DL, Gilgannon MD, Abel MF. Responsiveness and uniqueness of the pediatric outcomes data collection instrument compared to the gross motor function measure for measuring orthopaedic and neurosurgical outcomes in cerebral palsy. J Pediatr Orthop. 2005;25:641-645.
18. Graf A, Hassani S, Krzak J, et al. Gait characteristics and functional assessment of children with type I osteogenesis imperfecta. J Orthop Res. 2009;27:1182-1190.
19. Caudill A, Flanagan A, Hassani S, et al. Ankle strength and functional limitations in children and adolescents with type I osteogenesis imperfecta. Pediatr Phys Ther. 2010;22:288-295.
20. Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop. 2005;25:786-791.
21. Löwing K, Aström E, Oscarsson KA, et al. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Acta Paediatr. 2007;96:1180-1183.
22. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363: 1427-1431.
23. Daly K, Wisbeach A, Sanpera I Jr, et al. The prognosis for walking in osteogenesis imperfecta. J Bone Joint Surg Br. 1996;78:477-480.
24. Engelbert RHH, Uiterwaal CSPM, Gulmans VAM, et al. Osteogenesis imperfecta: profiles of motor development as assessed by a postal questionnaire. Eur J Pediatr. 2000;159:615-620.
25. Montpetit K, Dahan-Oliel N, Ruck-Gibis J, et al. Activities and participation in young adults with osteogenesis imperfecta. J Pediatr Rehabil Med. 2011;4:13-22.
26. Engelbert RH, Uiterwaal CS, Gerver W-J, et al. Osteogenesis imperfecta in childhood: Impairment and disability. a prospective study with 4-year follow-up. Arch Phys Med Rehabil. 2004;85:772-778.